Holen Sie sich die Stockscreener-App
1.74
4.82%
0.08
Handel nachbörslich:
1.72
-0.02
-1.15%
Schlusskurs vom Vortag:
$1.66
Offen:
$1.71
24-Stunden-Volumen:
1.37M
Relative Volume:
1.02
Marktkapitalisierung:
$93.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.69M
KGV:
-1.2518
EPS:
-1.39
Netto-Cashflow:
$-46.54M
1W Leistung:
+13.73%
1M Leistung:
+11.54%
6M Leistung:
-24.02%
1J Leistung:
+23.40%
1-Tages-Spanne:
$1.64
$1.74
1-Wochen-Bereich:
$1.48
$1.74
52-Wochen-Spanne:
$0.6254
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Firmenname
Milestone Pharmaceuticals Inc
Sektor
Branche
Telefon
(514) 336-0444
Adresse
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Vergleichen Sie MIST mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
1.74 | 141.04M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-06-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-07-24 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-24 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-03-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2019-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-03 | Eingeleitet | Cowen | Outperform |
| 2019-06-03 | Eingeleitet | Jefferies | Buy |
| 2019-06-03 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Milestone Pharmaceuticals Inc Aktie (MIST) Neueste Nachrichten
Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus - TipRanks
Milestone Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Announces FDA Acceptance of CARDAMYST™ CRL Response and Secures $170 Million in Public Offering - Quiver Quantitative
Milestone Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Short Interest Drops in Milestone Pharmaceuticals Inc. After RallyCapital Protection Trading Strategies Gain Interest - metal.it
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal - MSN
Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
What drives Milestone Pharmaceuticals Inc. stock priceAchieve rapid portfolio growth with smart picks - Jammu Links News
What analysts say about Milestone Pharmaceuticals Inc. stockCapitalize on market momentum for maximum profit - Jammu Links News
Should I hold or sell Milestone Pharmaceuticals Inc. stock in 2025Consistently outstanding ROI - Jammu Links News
How many analysts rate Milestone Pharmaceuticals Inc. as a “Buy”Exponential return rates - Jammu Links News
Is Milestone Pharmaceuticals Inc. stock overvalued or undervaluedFree Daily Trading Room Entry - Jammu Links News
How volatile is Milestone Pharmaceuticals Inc. stock compared to the marketInvest confidently with actionable market data - Jammu Links News
What are the latest earnings results for Milestone Pharmaceuticals Inc.Capitalize on emerging trends for profits - Jammu Links News
What are analysts’ price targets for Milestone Pharmaceuticals Inc. in the next 12 monthsTrack high-yield stocks before they peak - Jammu Links News
What catalysts could drive Milestone Pharmaceuticals Inc. stock higher in 2025Invest confidently with advanced analysis tools - Jammu Links News
How does Milestone Pharmaceuticals Inc. compare to its industry peersMaximize your gains with professional insights - Jammu Links News
Stock Market News for Aug 1, 2025 - The Globe and Mail
Why Milestone Pharmaceuticals Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Trading Bots Trigger Alerts on Milestone Pharmaceuticals Inc. ActivityReal Time Trade Opportunity Alerts Monitor Market Surges - metal.it
Can Milestone Pharmaceuticals Inc. hit a new high this monthSwing Setup With Technical Confirmation Explained - metal.it
RSI Suggests Rebound May Be Near in Milestone Pharmaceuticals Inc.Accurate Buy Point for Momentum Stocks Detected - metal.it
Published on: 2025-07-29 04:32:28 - beatles.ru
Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
Is it the right time to buy Milestone Pharmaceuticals Inc. stockFree Capital Allocation Plans - Jammu Links News
What makes Milestone Pharmaceuticals Inc. stock price move sharplyMaximize profits with strategic stock selection - Jammu Links News
How Efficient Is Milestone Pharmaceuticals Inc. at Controlling Operating CostsFree Stock Selection - metal.it
Is Milestone Pharmaceuticals Inc. stock a good hedge against inflationFree Access to Group - metal.it
Atrial Fibrillation (AF) Pipeline Market Research Report 2025 | Insights on 10+ Companies and 12+ Drugs in the Pipeline Landscape - GlobeNewswire Inc.
Is Milestone Pharmaceuticals Inc. a good long term investmentExtraordinary earning power - printweek.in
Milestone Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
Finanzdaten der Milestone Pharmaceuticals Inc-Aktie (MIST)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):